Wedbush Research Analysts Lift Earnings Estimates for KNSA

Key Points

• Wedbush Research analysts increased their Q3 2025 earnings per share estimate for Kiniksa Pharmaceuticals International from $0.25 to $0.43, maintaining an "Outperform" rating with a price target of $36.00.
• The company reported a quarterly EPS of $0.23, surpassing analysts' expectations of $0.18, alongside a revenue of $156.80 million, exceeding estimates of $145.21 million.
• Multiple other analysts have raised their price targets for Kiniksa, with Wells Fargo now at $42.00 and Jefferies at $54.00, indicating strong positive sentiment across the board.

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) - Stock analysts at Wedbush upped their Q3 2025 earnings per share estimates for Kiniksa Pharmaceuticals International in a report issued on Tuesday, July 29th. Wedbush analyst D. Nierengarten now expects that the company will earn $0.43 per share for the quarter, up from their previous estimate of $0.25. Wedbush has a "Outperform" rating and a $36.00 price objective on the stock. The consensus estimate for Kiniksa Pharmaceuticals International's current full-year earnings is ($0.55) per share. Wedbush also issued estimates for Kiniksa Pharmaceuticals International's Q4 2025 earnings at $0.47 EPS, FY2025 earnings at $1.27 EPS, Q1 2026 earnings at $0.48 EPS, Q2 2026 earnings at $0.55 EPS, Q3 2026 earnings at $0.62 EPS, Q4 2026 earnings at $0.68 EPS, FY2026 earnings at $2.34 EPS, FY2027 earnings at $3.15 EPS and FY2028 earnings at $3.28 EPS.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last issued its quarterly earnings results on Tuesday, July 29th. The company reported $0.23 EPS for the quarter, beating analysts' consensus estimates of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a return on equity of 1.05% and a net margin of 0.90%. The firm had revenue of $156.80 million for the quarter, compared to analysts' expectations of $145.21 million.

Other equities analysts also recently issued research reports about the stock. Wells Fargo & Company lifted their target price on shares of Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the stock an "overweight" rating in a research note on Wednesday, July 9th. Jefferies Financial Group raised their price objective on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a "buy" rating in a report on Tuesday. Finally, Wall Street Zen raised shares of Kiniksa Pharmaceuticals International from a "hold" rating to a "buy" rating in a report on Sunday, July 6th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $41.17.

Kiniksa Pharmaceuticals International Stock Performance

Shares of Kiniksa Pharmaceuticals International stock opened at $30.26 on Friday. The stock has a market capitalization of $2.21 billion, a P/E ratio of 756.69 and a beta of 0.05. Kiniksa Pharmaceuticals International has a 52-week low of $17.82 and a 52-week high of $31.92. The stock's 50-day simple moving average is $28.28 and its 200 day simple moving average is $23.97.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

A number of large investors have recently modified their holdings of KNSA. Wealth Enhancement Advisory Services LLC purchased a new position in shares of Kiniksa Pharmaceuticals International during the first quarter worth approximately $301,000. GAMMA Investing LLC grew its holdings in shares of Kiniksa Pharmaceuticals International by 84.8% during the 1st quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock valued at $27,000 after purchasing an additional 568 shares during the last quarter. Nuveen Asset Management LLC raised its position in Kiniksa Pharmaceuticals International by 7.3% in the 4th quarter. Nuveen Asset Management LLC now owns 795,612 shares of the company's stock worth $15,737,000 after purchasing an additional 54,361 shares during the period. Wellington Management Group LLP lifted its stake in Kiniksa Pharmaceuticals International by 46.3% in the fourth quarter. Wellington Management Group LLP now owns 69,813 shares of the company's stock worth $1,381,000 after purchasing an additional 22,096 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Kiniksa Pharmaceuticals International by 28.2% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 56,691 shares of the company's stock worth $1,121,000 after purchasing an additional 12,462 shares during the last quarter. 53.95% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, insider Ross Moat sold 27,594 shares of the business's stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $29.02, for a total transaction of $800,777.88. Following the completion of the transaction, the insider owned 9,415 shares of the company's stock, valued at approximately $273,223.30. The trade was a 74.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Eben Tessari sold 45,042 shares of the firm's stock in a transaction on Wednesday, June 11th. The shares were sold at an average price of $30.51, for a total transaction of $1,374,231.42. Following the completion of the transaction, the chief operating officer directly owned 72,363 shares of the company's stock, valued at approximately $2,207,795.13. The trade was a 38.36% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 320,981 shares of company stock valued at $9,189,467 in the last three months. Insiders own 53.48% of the company's stock.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.